N@N

Investrend aDiscoverya? Research On CelLynx By Analyst Vassalotti

^{Published on 2009-12-21 05:30:07 - Market Wire}
 

NEW YORK--([ BUSINESS WIRE ])--Investrend Equity Research has issued a 7-page "Discovery" Research Report on CelLynx Group, Inc. (OTCBB: CYNX) dated December 18, 2009, written by independent analyst Gary Vassalotti, LIFA, focusing on the company's "5BARz" cell phone signal amplification device, as well as the production, product placement and distribution of the device. The report is also based on analyst Vassalotti's personal experience using the 5BARz device.

"The RepeaterStore.com, a leading e-commerce retailer in the wireless booster market, has agreed to an initial purchase of 10,000 units of the company's 5BARz mobile unit. RepeaterStore.com will also develop a dedicated e-commerce site just for the CelLynx product, titled ‘CelLynxStore.com'."

The full report includes important disclosures, disclaimers and analyst information. Investrend advises investors to exercise a reasonable degree of due diligence before trading in the equities of any public company, including carefully reading entire analyst reports and report disclosures, and then only in conjunction with advice from a registered financial advisor or broker. Investrend further advises that any analyst rating, recommendation, target valuation, price target or opinion should be considered merely a portion of an investor's total investigative process. (More about ratings and valuations is available at [ http://www.investrend.com/ratings ]).

A complementary report, which includes complete disclosures, disclaimers and analyst qualifications, is available for download via the Investrend Syndications website ([ http://www.investrend.com/research/cynx ]).

According to analyst Vassalotti's report:

"The company has completed its pilot production run, and the units have been qualified. Commercial production has already started. With these two milestones passed, CYNX is now eligible to receive the first of a series of License fees paid by Dollardex, Inc.

"CYNX has signed a contract manufacturing agreements with a leading Asian firm, Pacific Spectrum Technologies Solutions, who will build the 5BARz boosters. That agreement will provides CYNX with up to 30,000 units per month.

"CYNX has signed an international distribution agreement with Dollardex, Inc., a Panamanian company, to distribute the Company's products outside of the US. That agreement, along with in-place private placement agreements, provides for adequate financing of the company during the revenue slow startup period.

"The RepeaterStore.com, a leading e-commerce retailer in the wireless booster market, has agreed to an initial purchase of 10,000 units of the company's 5BARz mobile unit. RepeaterStore.com will also develop a dedicated e-commerce site just for the CelLynx product, titled ‘CelLynxStore.com'.

"Initial production of the 'Road Warrior' unit has commenced and the contract manufacturer is beginning to fill the (previously mentioned) 10,000-unit initial order."

About CelLynx:

CelLynx Group, Inc. produces and markets plug-and-play cell phone signal amplification technology. It offers CelLynx 5BARz Road Warrior, a single piece device that strengthens weak cellular signals to deliver higher quality signals for voice, data, and video reception on cell phones being used indoors or in vehicles. The company was founded in 2005 and is headquartered in Mission Viejo, California.

About Investrend and Discovery Research

Investrend Communications, Inc. is the original, pioneering issuer-paid equity research firm, providing integrated research and global financial communications platforms for the benefit of shareholders and the Market at-large since 1996. Investrend is privately-held, and is headquartered in Austin, Texas, with offices in New York City.

Investrend's Discovery Research platform is designed to provide an analysis of the industry and industry niche that a company is operating in, as well as an analysis of the company's business model, including products, services, pricing, cost structure, and competitive advantage. Importantly, Investrend's Discovery Research model also focuses on identifying any existing "catalyst" that could lead to broader understanding and/or recognition of the company's investment story on Wall Street.

About The Investrend Research Syndicate:

The Investrend Research Syndicate ([ http://www.investrend.com/research/syndicate ]), a proprietary entity of Investrend Communications, Inc., distributes reports published by sources dedicated to unbiased, reliable analytics and complete transparency. The primary measure for determining those sources is the "Standards for Independent Research Providers" ([ http://www.investrend.com/FIRST/standards ]).

Disclosures:

CelLynx Group, Inc. ("CelLynx") has paid Investrend Communications, Inc. ("Investrend") six thousand US dollars to arrange for an independent analyst to write one "Discovery" Research Report and one follow-up, Update Report on CelLynx. CelLynx's payment to Investrend also provides that Investrend will facilitate a "Distribution and Visibility" Program in conjunction with and in support of Investrend's research coverage on CelLynx.

Full payment from CelLynx was (and will be) paid to Investrend prior to receipt of any report draft(s), and therefore has been (and will be) paid in-full prior to the issuance of any final report(s). The analyst writing CelLynx's report was (and will be) paid directly by Investrend prior to the issuance of any report draft(s) to CelLynx, and therefore has been (and will be) paid in-full prior to the issuance of any final report(s); and said payment to the writing analyst is not contingent on any "positive," "negative" or "neutral" sentiment being expressed in the analyst's report(s). In addition, no Investrend partner, owner, officer, employee or the analyst(s) writing regarding CelLynx holds a position in and/or engages in transactions with respect to the securities of CelLynx.

"Safe Harbor" Statement:

This announcement contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including statements regarding potential sales, the success of the company's business, as well as statements that include the word "believe" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of CelLynx Group, Inc. to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in reports filed with the SEC under the Exchange Act. This press release speaks as of the date first set forth above and CelLynx Group, Inc. assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, timely development of products and services, inability to deliver products and services when promised, inability of potential customers to pay for ordered products and services, and political and economic risks inherent in international trade.

Disclaimer:

The OTC Bulletin Board Exchange has neither approved nor accepts responsibility for the adequacy or accuracy of the above news release.